2023-12-13 Regulatorisk

Update on NeoDynamics’ management team

As a consequence of the cost reduction plan announced in November, Aaron Wong, CFO will be leaving NeoDynamics by end May 2024.

Aaron Wong, CFO joined NeoDynamics on 1st February 2022. Aaron has been instrumental in securing financing for the company’s operations and growth in the past couple of years while supporting the company’s strategic focus on securing FDA clearance and a commercial break-through in the US.

“Aaron has been a great support for the Board and Management Team and has excelled with his great understanding of the business and strategy combined with his strong CFO toolbox and mindset. I am grateful for Aaron’s huge contributions and wish him all the best in future.”, says Anna Eriksrud, CEO.

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.